Drug Profile
GMA 204
Alternative Names: GMA204Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Gmax Biopharm
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor inhibitors; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in China
- 11 Mar 2020 GMA 204 is still in preclinical trials for Non-small cell lung cancer in China (Gmax Biopharma pipeline, March 2020)